We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.
When a company wishes to "uplist" from pinksheets to NASDAQ it must first file S-1 and S-1a until final approval. Once final approval is obtained the SEC files a CERTNAS
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions